Prion-like mechanisms in neurodegenerative diseases

Nature Reviews Neuroscience

11, 155-159

DOI: 10.1038/nrn2786

Citation Report

#	Article	IF	Citations
1	Induction of Protective Immunity by Vaccination With Wild-Type Apo Superoxide Dismutase 1 in Mutant SOD1 Transgenic Mice. Journal of Neuropathology and Experimental Neurology, 2010, 69, 1044-1056.	0.9	78
2	Preparation and Characterization of Neurotoxic Tau Oligomers. Biochemistry, 2010, 49, 10039-10041.	1.2	302
3	Anterior insula degeneration in frontotemporal dementia. Brain Structure and Function, 2010, 214, 465-475.	1.2	141
4	Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice. EPMA Journal, 2010, 1, 305-316.	3.3	7
5	Are synucleinopathies prion-like disorders?. Lancet Neurology, The, 2010, 9, 1128-1138.	4.9	226
6	MicroRNAs as a molecular basis for mental retardation, Alzheimer's and prion diseases. Brain Research, 2010, 1338, 58-66.	1.1	67
7	Amyloid Assemblies: Protein Legos at a Crossroads in Bottomâ€Up Synthetic Biology. ChemBioChem, 2010, 11, 2347-2357.	1.3	29
8	Missing pieces in the Parkinson's disease puzzle. Nature Medicine, 2010, 16, 653-661.	15.2	621
9	Autophagy gone awry in neurodegenerative diseases. Nature Neuroscience, 2010, 13, 805-811.	7.1	805
10	Characterization of the Properties of a Novel Mutation in VAPB in Familial Amyotrophic Lateral Sclerosis. Journal of Biological Chemistry, 2010, 285, 40266-40281.	1.6	136
11	Three- and Four-repeat Tau Coassemble into Heterogeneous Filaments. Journal of Biological Chemistry, 2010, 285, 37920-37926.	1.6	56
12	A Size Threshold Limits Prion Transmission and Establishes Phenotypic Diversity. Science, 2010, 330, 680-683.	6.0	98
13	Phosphorylation Dynamics Regulate Hsp27-Mediated Rescue of Neuronal Plasticity Deficits in Tau Transgenic Mice. Journal of Neuroscience, 2010, 30, 15374-15382.	1.7	105
14	Immunomodulation for prion and prion-related diseases. Expert Review of Vaccines, 2010, 9, 1441-1452.	2.0	18
15	Tau Pathology and Future Therapeutics. Current Alzheimer Research, 2010, 7, 685-696.	0.7	41
16	Genetic Analysis of Pathways to Parkinson Disease. Neuron, 2010, 68, 201-206.	3.8	249
17	Transsynaptic Progression of Amyloid-Î²-Induced Neuronal Dysfunction within the Entorhinal-Hippocampal Network. Neuron, 2010, 68, 428-441.	3.8	279
18	The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends in Neurosciences, 2010, 33, 317-325.	4.2	402

#	Article	IF	Citations
19	Prion-Like Behavior of Amyloid-Î². Science, 2010, 330, 918-919.	6.0	26
20	Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3548-3553.	3.3	421
21	Proteomics Approach to Identify the Interacting Partners of Cellular Prion Protein and Characterization of Rab7a Interaction in Neuronal Cells. Journal of Proteome Research, 2011, 10, 3123-3135.	1.8	48
22	Generalization of the Prion Hypothesis to Other Neurodegenerative Diseases: An Imperfect Fit. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2011, 74, 1433-1459.	1.1	63
23	Characterization of Amyloid-Î² Granules in the Hippocampus of SAMP8 Mice. Journal of Alzheimer's Disease, 2011, 25, 535-546.	1.2	48
24	Toll-Like Receptor 4 Promotes Î±-Synuclein Clearance and Survival of Nigral Dopaminergic Neurons. American Journal of Pathology, 2011, 179, 954-963.	1.9	230
25	The intricate mechanisms of neurodegeneration in prion diseases. Trends in Molecular Medicine, 2011, 17, 14-24.	3.5	119
26	Role of the androgen receptor CAG repeat polymorphism in prostate cancer, and spinal and bulbar muscular atrophy. Life Sciences, 2011, 88, 565-571.	2.0	41
27	Selective Neuronal Vulnerability in Neurodegenerative Diseases: from Stressor Thresholds to Degeneration. Neuron, 2011, 71, 35-48.	3.8	465
28	Signs of Degeneration in 12â€“22-Year Old Grafts of Mesencephalic Dopamine Neurons in Patients with Parkinson's Disease. Journal of Parkinson's Disease, 2011, 1, 83-92.	1.5	90
29	Amyloid Oligomer Neurotoxicity, Calcium Dysregulation, and Lipid Rafts. International Journal of Alzheimer's Disease, 2011, 2011, 1-17.	1.1	34
30	.ALPHA.-Synuclein Aggregation and Transmission Are Enhanced by Leucine-Rich Repeat Kinase 2 in Human Neuroblastoma SH-SY5Y Cells. Biological and Pharmaceutical Bulletin, 2011, 34, 1078-1083.	0.6	43
31	Amyloid-Î² and tau â€" a toxic pas de deux in Alzheimer's disease. Nature Reviews Neuroscience, 2011, 12, 67-72.	4.9	1,147
32	Linking lipids to Alzheimer's disease: cholesterol and beyond. Nature Reviews Neuroscience, 2011, 12, 284-296.	4.9	751
33	A deadly spread: cellular mechanisms of Î±-synuclein transfer. Cell Death and Differentiation, 2011, 18, 1425-1433.	5.0	131
34	Prion hypothesis: the end of the controversy?. Trends in Biochemical Sciences, 2011, 36, 151-158.	3.7	152
35	Functional network disruption in the degenerative dementias. Lancet Neurology, The, 2011, 10, 829-843.	4.9	422
36	Variations in Filament Conformation Dictate Seeding Barrier between Three- and Four-Repeat Tau. Biochemistry, 2011, 50, 4330-4336.	1.2	81

#	Article	IF	Citations
37	Î±-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. Journal of Clinical Investigation, 2011, 121, 715-725.	3.9	722
38	Alzheimerâ€™s Disease: The Challenge of the Second Century. Science Translational Medicine, 2011, 3, 77sr1.	5.8	1,109
39	Reversibility of Tau-Related Cognitive Defects in a Regulatable FTD Mouse Model. Journal of Molecular Neuroscience, 2011, 45, 432-437.	1.1	42
40	Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Molecular Neurodegeneration, 2011, 6, 39.	4.4	462
41	Pathogenic protein seeding in alzheimer disease and other neurodegenerative disorders. Annals of Neurology, 2011, 70, 532-540.	2.8	536
42	Genetics of Dementia. Seminars in Neurology, 2011, 31, 449-460.	0.5	48
44	Propagation: Prion-like mechanisms can explain spreading of motor neuronal death in amyotrophic lateral sclerosis?. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1181-1182.	0.9	3
45	Implications of the prion-related Q/N domains in TDP-43 and FUS. Prion, 2011, 5, 1-5.	0.9	97
46	In VivoMicrodialysis Reveals Age-Dependent Decrease of Brain Interstitial Fluid Tau Levels in P301S Human Tau Transgenic Mice. Journal of Neuroscience, 2011, 31, 13110-13117.	1.7	309
47	Protein Misdirection Inside and Outside Motor Neurons in Amyotrophic Lateral Sclerosis (ALS): A Possible Clue for Therapeutic Strategies. International Journal of Molecular Sciences, 2011, 12, 6980-7003.	1.8	19
48	Genesis of Mammalian Prions: From Non-infectious Amyloid Fibrils to a Transmissible Prion Disease. PLoS Pathogens, 2011, 7, e1002419.	2.1	98
49	Prion Uptake in the Gut: Identification of the First Uptake and Replication Sites. PLoS Pathogens, 2011, 7, e1002449.	2.1	103
50	Where, when, and in what form does sporadic AlzheimerÊ¼s disease begin?. Current Opinion in Neurology, 2012, 25, 708-714.	1.8	202
51	Mutant p53 Aggregates into Prion-like Amyloid Oligomers and Fibrils. Journal of Biological Chemistry, 2012, 287, 28152-28162.	1.6	225
52	Molecular Basis of Prion Diseases. , 2012, , 872-885.		3
53	Molecular Pathology in Neurodegenerative Diseases. Current Drug Targets, 2012, 13, 1548-1559.	1.0	31
54	Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB Journal, 2012, 26, 1946-1959.	0.2	420
55	Reduced Calreticulin Levels Link Endoplasmic Reticulum Stress and Fas-Triggered Cell Death in Motoneurons Vulnerable to ALS. Journal of Neuroscience, 2012, 32, 4901-4912.	1.7	88

#	Article	IF	Citations
56	Toxic prefibrillar Î±-synuclein amyloid oligomers adopt a distinctive antiparallel Î²-sheet structure. Biochemical Journal, 2012, 443, 719-726.	1.7	215
57	Functional Genomics Approach for Identification of Molecular Processes Underlying Neurodegenerative Disorders in Prion Diseases. Current Genomics, 2012, 13, 369-378.	0.7	11
58	Network models of dementia progression: the way forward?. Future Neurology, 2012, 7, 659-662.	0.9	0
59	Neuropathology in transplants in Parkinson's disease. Progress in Brain Research, 2012, 200, 221-241.	0.9	43
60	The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update. Expert Opinion on Drug Discovery, 2012, 7, 281-297.	2.5	42
61	Characterization of the novel protein P9TLDR (temporal lobe downâ€regulated) with a brainâ€siteâ€specific gene expression modality in Alzheimer's disease brain. FEBS Letters, 2012, 586, 4357-4361.	1.3	2
62	Total allowable concentrations of monomeric inorganic aluminum and hydrated aluminum silicates in drinking water. Critical Reviews in Toxicology, 2012, 42, 358-442.	1.9	86
63	Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. Journal of Neuroinflammation, 2012, 9, 179.	3.1	423
64	Fibrils Colocalize Caspase-3 with Procaspase-3 to Foster Maturation. Journal of Biological Chemistry, 2012, 287, 33781-33795.	1.6	45
65	Sporadic human prion diseases: molecular insights and diagnosis. Lancet Neurology, The, 2012, 11, 618-628.	4.9	319
66	Hsp104 Gives Clients the Individual Attention They Need. Cell, 2012, 151, 695-697.	13.5	7
67	A New Mechanism for Transmissible Prion Diseases. Journal of Neuroscience, 2012, 32, 7345-7355.	1.7	72
68	Amyloid neuropathology in the single Arctic APP transgenic model affects interconnected brain regions. Neurobiology of Aging, 2012, 33, 831.e11-831.e19.	1.5	40
69	A Network Diffusion Model of Disease Progression in Dementia. Neuron, 2012, 73, 1204-1215.	3.8	582
70	Predicting Regional Neurodegeneration from the Healthy Brain Functional Connectome. Neuron, 2012, 73, 1216-1227.	3.8	605
71	Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. Progress in Neurobiology, 2012, 97, 38-51.	2.8	153
72	Prion protein at the crossroads of physiology and disease. Trends in Neurosciences, 2012, 35, 92-103.	4.2	150
73	De novo induction of amyloid-Î² deposition in vivo. Molecular Psychiatry, 2012, 17, 1347-1353.	4.1	163

#	Article	IF	Citations
74	Proteolytic Cleavage of Extracellular Î±-Synuclein by Plasmin. Journal of Biological Chemistry, 2012, 287, 24862-24872.	1.6	67
75	Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO Journal, 2012, 31, 3038-3062.	3.5	487
76	Beyond Î±-synuclein transfer: pathology propagation in Parkinson's disease. Trends in Molecular Medicine, 2012, 18, 248-255.	3.5	69
77	Differentiating Prion Strains Using Dendrimers. Advanced Healthcare Materials, 2012, 1, 768-772.	3.9	19
78	Alzheimerâ€™s disease AÎ² assemblies mediating rapid disruption of synaptic plasticity and memory. Molecular Brain, 2012, 5, 25.	1.3	82
79	Role of Ser129 phosphorylation of Î±-synuclein in melanoma cells. Journal of Cell Science, 2013, 126, 696-704.	1.2	32
80	The epidemiological neuropathology of dementia and the implications for drug development. Neurodegenerative Disease Management, 2012, 2, 471-482.	1.2	7
81	Reconciling Braakâ€™s model of Parkinsonâ€™s disease with a prion-like spread of alpha synuclein pathology. Basal Ganglia, 2012, 2, 167-170.	0.3	2
82	Degradation of Fungal Prion HET-s(218-289) Induces Formation ofÂa Generic Amyloid Fold. Biophysical Journal, 2012, 102, 2339-2344.	0.2	24
83	Linking white matter integrity loss to associated cortical regions using structural connectivity information in Alzheimer's disease and fronto-temporal dementia: The Loss in Connectivity (LoCo) score. NeuroImage, 2012, 61, 1311-1323.	2.1	26
84	Fiber Diffraction Data Indicate a Hollow Core for the Alzheimer's AÎ² 3-Fold Symmetric Fibril. Journal of Molecular Biology, 2012, 423, 454-461.	2.0	34
85	Frontal Cortex Neuropathology in Dementia Pugilistica. Journal of Neurotrauma, 2012, 29, 1054-1070.	1.7	77
86	Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Scientific Reports, 2012, 2, 700.	1.6	396
87	Suppression of dynamin GTPase decreases Î±-synuclein uptake by neuronal and oligodendroglial cells: a potent therapeutic target for synucleinopathy. Molecular Neurodegeneration, 2012, 7, 38.	4.4	107
88	Human P301L-Mutant Tau Expression in Mouse Entorhinal-Hippocampal Network Causes Tau Aggregation and Presynaptic Pathology but No Cognitive Deficits. PLoS ONE, 2012, 7, e45881.	1.1	111
89	Hsp40 Gene Therapy Exerts Therapeutic Effects on Polyglutamine Disease Mice via a Non-Cell Autonomous Mechanism. PLoS ONE, 2012, 7, e51069.	1.1	38
90	From Molecule to Clinic and Community for Neurodegeneration: Research to Bridge Translational Gaps. Journal of Alzheimer's Disease, 2012, 33, S385-S396.	1.2	5
92	Detection of Mutant Huntingtin Aggregation Conformers and Modulation of SDS-Soluble Fibrillar Oligomers by Small Molecules. Journal of Huntington's Disease, 2012, 1, 119-132.	0.9	24

#	Article	IF	Citations
93	The role of RNA in mammalian prion protein conversion. Wiley Interdisciplinary Reviews RNA, 2012, 3, 415-428.	3.2	26
94	The contribution of different prion protein types and host polymorphisms to clinicopathological variations in Creutzfeldtâ€“Jakob disease. Reviews in Medical Virology, 2012, 22, 214-229.	3.9	10
95	Regulation and cellular functions of class II phosphoinositide 3-kinases. Biochemical Journal, 2012, 443, 587-601.	1.7	141
96	Cross-seeding and Conformational Selection between Three- and Four-repeat Human Tau Proteins. Journal of Biological Chemistry, 2012, 287, 14950-14959.	1.6	63
97	High-resolution structure of infectious prion protein: the final frontier. Nature Structural and Molecular Biology, 2012, 19, 370-377.	3.6	113
99	Interaction between pathogenic proteins in neurodegenerative disorders. Journal of Cellular and Molecular Medicine, 2012, 16, 1166-1183.	1.6	104
100	Analyzing complicated protein folding kinetics rapidly by analytical Laplace inversion using a Tikhonov regularization variant. Analytical Biochemistry, 2012, 421, 181-190.	1.1	7
101	Prion-induced toxicity in PrP transgenic Drosophila. Experimental and Molecular Pathology, 2012, 92, 194-201.	0.9	31
102	Review: Creutzfeldtâ€“Jakob disease: prion protein type, disease phenotype and agent strain. Neuropathology and Applied Neurobiology, 2012, 38, 296-310.	1.8	72
103	Structural Basis of Î²â€Amyloidâ€Dependent Synaptic Dysfunctions. Angewandte Chemie - International Edition, 2012, 51, 1576-1579.	7.2	57
104	p53 Aggregates Penetrate Cells and Induce the Co-Aggregation of Intracellular p53. PLoS ONE, 2013, 8, e69242.	1.1	53
105	Small RNA drugs for prion disease: a new frontier. Expert Opinion on Drug Discovery, 2013, 8, 1265-1284.	2.5	7
106	Amyloid plaque pathogenesis in 5XFAD mouse spinal cord: retrograde transneuronal modulation after peripheral nerve injury. Neurotoxicity Research, 2013, 24, 1-14.	1.3	16
107	The prion hypothesis in Parkinson's disease: Braak to the future. Acta Neuropathologica Communications, 2013, 1, 2.	2.4	205
108	Î±-Synuclein and Neuronal Cell Death. Molecular Neurobiology, 2013, 47, 466-483.	1.9	97
109	Inclusion body formation, macroautophagy, and the role of HDAC6 in neurodegeneration. Acta Neuropathologica, 2013, 126, 793-807.	3.9	94
110	Molecular nexopathies: a new paradigm of neurodegenerative disease. Trends in Neurosciences, 2013, 36, 561-569.	4.2	223
111	Human prion diseases: Molecular, cellular and population biology. Neuropathology, 2013, 33, 221-236.	0.7	32

#	Article	IF	Citations
112	Garbage Truck of the Brain. Science, 2013, 340, 1529-1530.	6.0	526
113	Anti-Tau Antibodies that Block Tau Aggregate Seeding InÂVitro Markedly Decrease Pathology and Improve Cognition InÂVivo. Neuron, 2013, 80, 402-414.	3.8	483
114	Proteopathic Seeds and Neurodegenerative Diseases. Research and Perspectives in Alzheimer's Disease, 2013, , .	0.1	4
115	Immunotherapy for neurodegenerative diseases: Focus on Î±-synucleinopathies. , 2013, 138, 311-322.		115
116	The cell biology of prion-like spread of protein aggregates: mechanisms and implication in neurodegeneration. Biochemical Journal, 2013, 452, 1-17.	1.7	126
118	Brain site-specific proteome changes in aging-related dementia. Experimental and Molecular Medicine, 2013, 45, e39-e39.	3.2	98
119	Evidence for Age-Dependent in Vivo Conformational Rearrangement within AÎ² Amyloid Deposits. ACS Chemical Biology, 2013, 8, 1128-1133.	1.6	93
120	Mechanisms of Protein Seeding in Neurodegenerative Diseases. JAMA Neurology, 2013, 70, 304.	4.5	195
121	New Perspectives on Prion Conversion: Introducing a Mechanism of Deformed Templating. , 2013, , 121-133.		1
122	Pharmacokinetics and Metabolism of 2-Aminothiazoles with Antiprion Activity in Mice. Pharmaceutical Research, 2013, 30, 932-950.	1.7	29
123	Aggregation and neurotoxicity of recombinant Î±-synuclein aggregates initiated by dimerization. Molecular Neurodegeneration, 2013, 8, 5.	4.4	71
124	MicroRNAs in the Brain: It's Regulatory Role in Neuroinflammation. Molecular Neurobiology, 2013, 47, 1034-1044.	1.9	61
125	Proteolytic clearance of extracellular Î±-synuclein as a new therapeutic approach against Parkinson disease. Prion, 2013, 7, 121-126.	0.9	20
126	Prion-like mechanisms in epileptogenesis. Neurological Sciences, 2013, 34, 1035-1038.	0.9	5
127	Opportunities and Challenges for Molecular Chaperone Modulation to Treat Protein-Conformational Brain Diseases. Neurotherapeutics, 2013, 10, 416-428.	2.1	13
128	Inhibition of Protein Misfolding/Aggregation Using Polyglutamine Binding Peptide QBP1 as a Therapy for the Polyglutamine Diseases. Neurotherapeutics, 2013, 10, 440-446.	2.1	30
129	The Prion-Like Aspect of Alzheimer Pathology. Research and Perspectives in Alzheimer's Disease, 2013, , 61-69.	0.1	2
130	Anatomical Brain Networks on the Prediction of Abnormal Brain States. Brain Connectivity, 2013, 3, 1-21.	0.8	44

#	Article	IF	Citations
131	Alzheimer disease. Prion, 2013, 7, 14-19.	0.9	108
132	Natural Compounds May Open New Routes to Treatment of Amyloid Diseases. Neurotherapeutics, 2013, 10, 429-439.	2.1	75
133	Networks of anatomical covariance. NeuroImage, 2013, 80, 489-504.	2.1	355
135	Protein Structure and Biology: Poster Abstracts. Prion, 2013, 7, 81-104.	0.9	1
136	Antibody Uptake into Neurons Occurs Primarily via Clathrin-dependent FcÎ³ Receptor Endocytosis and Is a Prerequisite for Acute Tau Protein Clearance. Journal of Biological Chemistry, 2013, 288, 35452-35465.	1.6	171
137	Dissociation of Prion Protein Amyloid Seeding from Transmission of a Spongiform Encephalopathy. Journal of Virology, 2013, 87, 12349-12356.	1.5	23
138	Rapid Accumulation of Endogenous Tau Oligomers in a Rat Model of Traumatic Brain Injury. Journal of Biological Chemistry, 2013, 288, 17042-17050.	1.6	115
139	Convergence of Synapses, Endosomes, and Prions in the Biology of Neurodegenerative Diseases. International Journal of Cell Biology, 2013, 2013, 1-6.	1.0	16
140	Spreading of tau pathology in <scp>A</scp>lzheimer's disease by cellâ€toâ€cell transmission. European Journal of Neuroscience, 2013, 37, 1939-1948.	1.2	106
141	Regulatable transgenic mouse models of <scp>A</scp>lzheimer disease: onset, reversibility and spreading of <scp>T</scp>au pathology. FEBS Journal, 2013, 280, 4371-4381.	2.2	63
142	Context dependence of protein misfolding and structural strains in neurodegenerative diseases. Biopolymers, 2013, 100, 722-730.	1.2	13
143	Prions and Diseases. , 2013, , .		0
144	Stress granules as crucibles of ALS pathogenesis. Journal of Cell Biology, 2013, 201, 361-372.	2.3	756
146	Profoundly different prion diseases in knock-in mice carrying single PrP codon substitutions associated with human diseases. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 14759-14764.	3.3	47
147	Propagation of tau pathology in Alzheimerâ€™s disease: identification of novel therapeutic targets. Alzheimer's Research and Therapy, 2013, 5, 49.	3.0	84
148	Before the Tremor: Premotor Symptoms of Parkinsonâ€™s Disease. Environmental Health Perspectives, 2013, 121, A342.	2.8	0
149	A 43-kDa TDP-43 Species Is Present in Aggregates Associated with Frontotemporal Lobar Degeneration. PLoS ONE, 2013, 8, e62301.	1.1	9
150	Amyloid-Like Fibril Elongation Follows Michaelis-Menten Kinetics. PLoS ONE, 2013, 8, e68684.	1.1	17

#	Article	IF	Citations
151	Alzheimer's Disease and Prion Protein. Intractable and Rare Diseases Research, 2013, 2, 35-44.	0.3	15
153	Î²-Hairpin-Mediated Formation of Structurally Distinct Multimers of Neurotoxic Prion Peptides. PLoS ONE, 2014, 9, e87354.	1.1	21
154	Elongation of Mouse Prion Protein Amyloid-Like Fibrils: Effect of Temperature and Denaturant Concentration. PLoS ONE, 2014, 9, e94469.	1.1	23
155	Biochemical Assessment of Precuneus and Posterior Cingulate Gyrus in the Context of Brain Aging and Alzheimerâ€™s Disease. PLoS ONE, 2014, 9, e105784.	1.1	16
156	Cannabinoids for treatment of AlzheimerÃ¢â‚¬â„¢s disease: moving toward the clinic. Frontiers in Pharmacology, 2014, 5, 37.	1.6	166
157	Rescue of tau-induced synaptic transmission pathology by paclitaxel. Frontiers in Cellular Neuroscience, 2014, 8, 34.	1.8	18
158	The triple power of DÂ³: Protein intrinsic disorder in degenerative diseases. Frontiers in Bioscience - Landmark, 2014, 19, 181.	3.0	78
160	Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2014, 2, 146.	2.4	79
161	Extracellular Monomeric Tau Protein Is Sufficient to Initiate the Spread of Tau Protein Pathology. Journal of Biological Chemistry, 2014, 289, 956-967.	1.6	153
162	Stages and Conformations of the Tau Repeat Domain during Aggregation and Its Effect on Neuronal Toxicity. Journal of Biological Chemistry, 2014, 289, 20318-20332.	1.6	77
163	Mechanisms of amyloid fibril formation. Biochemistry (Moscow), 2014, 79, 1515-1527.	0.7	15
164	Advances in MRI biomarkers for the diagnosis of Alzheimer's disease. Biomarkers in Medicine, 2014, 8, 1151-1169.	0.6	47
165	The sleepâ€“wake cycle and Alzheimer's disease: what do we know?. Neurodegenerative Disease Management, 2014, 4, 351-362.	1.2	118
166	Epidemic Spreading Model to Characterize Misfolded Proteins Propagation in Aging and Associated Neurodegenerative Disorders. PLoS Computational Biology, 2014, 10, e1003956.	1.5	151
167	Selective vulnerability to neurodegenerative disease: the curious case of Prion Protein. DMM Disease Models and Mechanisms, 2014, 7, 21-29.	1.2	74
168	Impairment of Glymphatic Pathway Function Promotes Tau Pathology after Traumatic Brain Injury. Journal of Neuroscience, 2014, 34, 16180-16193.	1.7	797
169	Lost after translation: missorting of Tau protein and consequences for Alzheimer disease. Trends in Neurosciences, 2014, 37, 721-732.	4.2	221
170	Study of low-frequency dynamics of short peptides by Brillouin light scattering and Monte-Carlo global energy minimization. Journal of Physics: Conference Series, 2014, 572, 012015.	0.3	2

#	Article	IF	Citations
171	Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimerâ€˜s disease. Brain, 2014, 137, 2834-2846.	3.7	179
172	Altered CpG methylation in sporadic Alzheimer's disease is associated with APP and MAPT dysregulation. Human Molecular Genetics, 2014, 23, 648-656.	1.4	126
173	Polymorphism of Amyloid Fibrils and their Complexes with Catalase. , 2014, , 255-262.		1
175	MicroRNAs meet calcium: Joint venture in ER proteostasis. Science Signaling, 2014, 7, re11.	1.6	9
176	Fungal prion HET-s as a model for structural complexity and self-propagation in prions. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5201-5206.	3.3	28
178	Towards translational therapies for multiple system atrophy. Progress in Neurobiology, 2014, 118, 19-35.	2.8	35
179	Protein aggregation and prionopathies. Pathologie Et Biologie, 2014, 62, 162-168.	2.2	23
180	Lesion of the subiculum reduces the spread of amyloid beta pathology to interconnected brain regions in a mouse model of Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2014, 2, 17.	2.4	17
181	A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathologica, 2014, 127, 667-683.	3.9	390
182	PrionScan: an online database of predicted prion domains in complete proteomes. BMC Genomics, 2014, 15, 102.	1.2	42
183	Oxidative Stress Promotes Uptake, Accumulation, and Oligomerization of Extracellular Î±-Synuclein in Oligodendrocytes. Journal of Molecular Neuroscience, 2014, 52, 339-352.	1.1	40
184	Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles. Journal of Neuroscience, 2014, 34, 4260-4272.	1.7	241
185	Intracellular and Extracellular Roles for Tau in Neurodegenerative Disease. Journal of Alzheimer's Disease, 2014, 40, S37-S45.	1.2	45
186	Network Dysfunction in Alzheimerâ€™s Disease and Frontotemporal Dementia: Implications for Psychiatry. Biological Psychiatry, 2014, 75, 565-573.	0.7	194
187	The role of the posterior cingulate cortex in cognition and disease. Brain, 2014, 137, 12-32.	3.7	1,721
188	The role of FUS gene variants in neurodegenerative diseases. Nature Reviews Neurology, 2014, 10, 337-348.	4.9	261
189	Systems Approach to Neurodegenerative Disease Biomarker Discovery. Annual Review of Pharmacology and Toxicology, 2014, 54, 457-481.	4.2	45
190	Tau-aggregation inhibitor therapy for Alzheimer's disease. Biochemical Pharmacology, 2014, 88, 529-539.	2.0	221

#	Article	IF	Citations
191	Alphaâ€synuclein transfers from neurons to oligodendrocytes. Glia, 2014, 62, 387-398.	2.5	215
192	A role for sleep disorders in pregnancy complications: challenges and opportunities. American Journal of Obstetrics and Gynecology, 2014, 210, 3-11.	0.7	40
193	A two population model of prion transport through a tunnelling nanotube. Computer Methods in Biomechanics and Biomedical Engineering, 2014, 17, 1705-1715.	0.9	2
194	Mutant PrPCJD prevails over wild-type PrPCJD in the brain of V210I and R208H genetic Creutzfeldtâ€"Jakob disease patients. Biochemical and Biophysical Research Communications, 2014, 454, 289-294.	1.0	6
195	Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathologica, 2014, 128, 755-766.	3.9	1,060
196	Alzheimerâ€™s Disease, Anesthesia, and Surgery: A Clinically Focused Review. Journal of Cardiothoracic and Vascular Anesthesia, 2014, 28, 1609-1623.	0.6	39
197	Relationships between cobalamin, epidermal growth factor, and normal prions in the myelin maintenance of central nervous system. International Journal of Biochemistry and Cell Biology, 2014, 55, 232-241.	1.2	19
198	Prion-like Mechanisms in the Pathogenesis of Tauopathies and Synucleinopathies. Current Neurology and Neuroscience Reports, 2014, 14, 495.	2.0	111
199	Amyloid-associated activity contributes to the severity and toxicity of a prion phenotype. Nature Communications, 2014, 5, 4384.	5.8	39
200	Structural Insights into Amyloid Oligomers of the Parkinson Disease-related Protein Î±-Synuclein. Journal of Biological Chemistry, 2014, 289, 26733-26742.	1.6	49
201	Impairment of paravascular clearance pathways in the aging brain. Annals of Neurology, 2014, 76, 845-861.	2.8	964
202	Proteopathic tau seeding predicts tauopathy in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4376-85.	3.3	474
203	Structureâ€"Activity Relationship Study around Guanabenz Identifies Two Derivatives Retaining Antiprion Activity but Having Lost Î±2-Adrenergic Receptor Agonistic Activity. ACS Chemical Neuroscience, 2014, 5, 1075-1082.	1.7	25
204	Structural connectivity of the default mode network and cognition in Alzheimer×³s disease. Psychiatry Research - Neuroimaging, 2014, 223, 15-22.	0.9	23
205	Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies. Neuron, 2014, 82, 1271-1288.	3.8	822
206	Evaluation of the antiprion activity of 6-aminophenanthridines and related heterocycles. European Journal of Medicinal Chemistry, 2014, 82, 363-371.	2.6	13
207	Protein phosphorylation in neurodegeneration: friend or foe?. Frontiers in Molecular Neuroscience, 2014, 7, 42.	1.4	203
208	Harnessing the Immune System for Treatment and Detection of Tau Pathology. Journal of Alzheimer's Disease, 2014, 40, S113-S121.	1.2	18

#	Article	IF	Citations
209	Vaccination with Sarkosyl Insoluble PHF-Tau Decrease Neurofibrillary Tangles Formation in Aged Tau Transgenic Mouse Model: A Pilot Study. Journal of Alzheimer's Disease, 2014, 40, S135-S145.	1.2	18
210	Single Mutations in Tau Modulate the Populations of Fibril Conformers through Seed Selection. Angewandte Chemie - International Edition, 2014, 53, 1590-1593.	7.2	38
211	Antiâ€tau antibody reduces insoluble tau and decreases brain atrophy. Annals of Clinical and Translational Neurology, 2015, 2, 278-288.	1.7	145
212	Review: Prionâ€like mechanisms of transactive response DNA binding protein of 43â€‰kDa (<scp>TDP</scp>â€43) in amyotrophic lateral sclerosis (<scp>ALS</scp>). Neuropathology and Applied Neurobiology, 2015, 41, 578-597.	1.8	76
213	Starvation and inhibition of lysosomal function increased tau secretion by primary cortical neurons. Scientific Reports, 2014, 4, 5715.	1.6	77
214	Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody. Scientific Reports, 2015, 5, 11161.	1.6	170
215	Sensitive Detection of Proteopathic Seeding Activity with FRET Flow Cytometry. Journal of Visualized Experiments, 2015, , e53205.	0.2	60
216	Immunotherapy in Parkinsonâ€™s Disease: Micromanaging Alpha-Synuclein Aggregation. Journal of Parkinson's Disease, 2015, 5, 413-424.	1.5	69
217	Mitochondrial impairment and oxidative stress compromise autophagosomal degradation of Î±â€synuclein in oligodendroglial cells. Journal of Neurochemistry, 2015, 135, 194-205.	2.1	36
218	Epicentral Disruption of Structural Connectivity in Alzheimer's Disease. CNS Neuroscience and Therapeutics, 2015, 21, 837-845.	1.9	36
220	Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson's disease. Frontiers in Neuroscience, 2015, 9, 59.	1.4	97
221	The role of macropinocytosis in the propagation of protein aggregation associated with neurodegenerative diseases. Frontiers in Physiology, 2015, 6, 277.	1.3	45
222	Network structure of brain atrophy in de novo Parkinson's disease. ELife, 2015, 4, .	2.8	187
223	Polymorphism of amyloid-like fibrils can be defined by the concentration of seeds. PeerJ, 2015, 3, e1207.	0.9	17
224	A mechanistic model of tau amyloid aggregation based on direct observation of oligomers. Nature Communications, 2015, 6, 7025.	5.8	179
225	Beta-Amyloid and Tau-Protein: Structure, Interaction, and Prion-Like Properties. Biochemistry (Moscow), 2015, 80, 1800-1819.	0.7	31
226	Loss of parkin promotes lipid rafts-dependent endocytosis through accumulating caveolin-1: implications for Parkinsonâ€™s disease. Molecular Neurodegeneration, 2015, 10, 63.	4.4	47
227	The connectomics of brain disorders. Nature Reviews Neuroscience, 2015, 16, 159-172.	4.9	1,315

#	Article	IF	Citations
228	Network Diffusion Model of Progression Predicts Longitudinal Patterns of Atrophy and Metabolism in Alzheimerâ€™s Disease. Cell Reports, 2015, 10, 359-369.	2.9	177
229	Aggregation of polyglutamine-expanded ataxin-3 sequesters its specific interacting partners into inclusions: Implication in a loss-of-function pathology. Scientific Reports, 2014, 4, 6410.	1.6	110
230	Quantitative assessment of prion infectivity in tissues and body fluids by real-time quaking-induced conversion. Journal of General Virology, 2015, 96, 210-219.	1.3	97
231	Pin1 dysregulation helps to explain the inverse association between cancer and Alzheimer's disease. Biochimica Et Biophysica Acta - General Subjects, 2015, 1850, 2069-2076.	1.1	84
232	Sequence-dependent Internalization of Aggregating Peptides. Journal of Biological Chemistry, 2015, 290, 242-258.	1.6	22
233	A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1246-1259.	0.4	50
234	Amyotrophic lateral sclerosis: Is the spinal fluid pathway involved in seeding and spread?. Medical Hypotheses, 2015, 85, 576-583.	0.8	22
235	Primary cilia and autophagic dysfunction in Huntingtonâ€™s disease. Cell Death and Differentiation, 2015, 22, 1413-1424.	5.0	32
236	Prenatal Infection. , 2015, , 67-87.		0
237	Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimerâ€™s and Parkinsonâ€™s disease. Acta Neuropathologica, 2015, 129, 527-540.	3.9	255
238	The Prion Hypothesis of Parkinsonâ€™s Disease. Current Neurology and Neuroscience Reports, 2015, 15, 28.	2.0	64
240	Mechanical properties of amyloid-like fibrils defined by secondary structures. Nanoscale, 2015, 7, 7745-7752.	2.8	34
241	Huntington disease. Nature Reviews Disease Primers, 2015, 1, 15005.	18.1	1,031
242	FTD and ALSâ€”translating mouse studies into clinical trials. Nature Reviews Neurology, 2015, 11, 360-366.	4.9	64
243	Aberrant cerebral network topology and mild cognitive impairment in early Parkinson's disease. Human Brain Mapping, 2015, 36, 2980-2995.	1.9	87
244	Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice. Acta Neuropathologica, 2015, 129, 875-894.	3.9	122
245	Passive immunotherapy of tauopathy targeting pSer413â€tau: a pilot study in mice. Annals of Clinical and Translational Neurology, 2015, 2, 241-255.	1.7	54
246	The preclinical phase of the pathological process underlying sporadic Alzheimerâ€™s disease. Brain, 2015, 138, 2814-2833.	3.7	380

#	Article	IF	Citations
247	Tau Protein. , 2015, , 857-874.		2
248	Neuroanatomy and Pathology of Sporadic Alzheimer's Disease. Advances in Anatomy, Embryology and Cell Biology, 2015, , .	1.0	81
249	Decoding the function of the N-terminal tail of the cellular prion protein to inspire novel therapeutic avenues for neurodegenerative diseases. Virus Research, 2015, 207, 62-68.	1.1	9
250	Invited review: Prionâ€like transmission and spreading of tau pathology. Neuropathology and Applied Neurobiology, 2015, 41, 47-58.	1.8	130
251	Connectomics: A new paradigm for understanding brain disease. European Neuropsychopharmacology, 2015, 25, 733-748.	0.3	187
252	Novel therapeutic strategy for neurodegeneration by blocking AÎ² seeding mediated aggregation in models of Alzheimer's disease. Neurobiology of Disease, 2015, 74, 144-157.	2.1	26
253	At the interface of sensory and motor dysfunctions and Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 70-98.	0.4	420
254	Spreading of Î±-synuclein in the face of axonal transport deficits in Parkinson's disease: A speculative synthesis. Neurobiology of Disease, 2015, 77, 276-283.	2.1	59
255	Modulators of Amyloid Î²-Protein (AÎ²) Self-Assembly. , 2016, , 97-191.		6
256	Insight into the Molecular Imaging of Alzheimerâ€™s Disease. International Journal of Biomedical Imaging, 2016, 2016, 1-17.	3.0	16
257	Connectivity Disruption, Atrophy, and Hypometabolism within Posterior Cingulate Networks in Alzheimer's Disease. Frontiers in Neuroscience, 2016, 10, 582.	1.4	42
258	Molecular Mechanisms in the Pathogenesis of Alzheimerâ€™s disease and Tauopathies-Prion-Like Seeded Aggregation and Phosphorylation. Biomolecules, 2016, 6, 24.	1.8	53
259	Predictive Big Data Analytics: A Study of Parkinsonâ€™s Disease Using Large, Complex, Heterogeneous, Incongruent, Multi-Source and Incomplete Observations. PLoS ONE, 2016, 11, e0157077.	1.1	94
260	Advanced imaging of tau pathology in Alzheimer Disease: New perspectives from super resolution microscopy and labelâ€free nanoscopy. Microscopy Research and Technique, 2016, 79, 677-683.	1.2	13
261	Calcium channel blockade attenuates abnormal synaptic transmission in the dentate gyrus elicited by entorhinal amyloidopathy. Synapse, 2016, 70, 408-417.	0.6	17
262	Bacoside-A, an anti-amyloid natural substance, inhibits membrane disruption by the amyloidogenic determinant of prion protein through accelerating fibril formation. Biochimica Et Biophysica Acta - Biomembranes, 2016, 1858, 2208-2214.	1.4	18
263	Extracellular Vesicles Containing P301L Mutant Tau Accelerate Pathological Tau Phosphorylation and Oligomer Formation but Do Not Seed Mature Neurofibrillary Tangles in ALZ17 Mice. Journal of Alzheimer's Disease, 2016, 54, 1207-1217.	1.2	69
264	Netrin-1 Interrupts Amyloid-Î² Amplification, Increases sAÎ²PPÎ± in vitro and in vivo, and Improves Cognition in a Mouse Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 52, 223-242.	1.2	22

#	Article	IF	Citations
265	The Brainâ€™s Structural Connectome Mediates the Relationship between Regional Neuroimaging Biomarkers inÂAlzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 1639-1657.	1.2	18
266	Transmission of Neurodegenerative Disorders Through Blood Transfusion. Annals of Internal Medicine, 2016, 165, 316.	2.0	40
267	Protein Misfolding in Prion and Prion-Like Diseases: Reconsidering a Required Role for Protein Loss-of-Function. Journal of Alzheimer's Disease, 2016, 54, 3-29.	1.2	17
268	Extracellular Vesicles Isolated from the Brains of rTg4510 Mice Seed Tau Protein Aggregation in a Threshold-dependent Manner. Journal of Biological Chemistry, 2016, 291, 12445-12466.	1.6	208
269	Proteostasis impairment in ALS. Brain Research, 2016, 1648, 571-579.	1.1	73
270	Selective expression of mutant huntingtin during development recapitulates characteristic features of Huntingtonâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 5736-5741.	3.3	117
271	What amyloid ligands can tell us about molecular polymorphism and disease. Neurobiology of Aging, 2016, 42, 205-212.	1.5	11
272	Amyloid-Î²(1â€“42) Aggregation Initiates Its Cellular Uptake and Cytotoxicity. Journal of Biological Chemistry, 2016, 291, 19590-19606.	1.6	91
274	Insights into White Matter Damage in Alzheimer's Disease: From Postmortem to in vivo Diffusion Tensor MRI Studies. Neurodegenerative Diseases, 2016, 16, 26-33.	0.8	42
275	Potential mechanisms and implications for the formation of tau oligomeric strains. Critical Reviews in Biochemistry and Molecular Biology, 2016, 51, 482-496.	2.3	64
276	Statistical Connectomics. , 2016, , 383-419.		2
277	Healthy brain connectivity predicts atrophy progression in non-fluent variant of primary progressive aphasia. Brain, 2016, 139, 2778-2791.	3.7	108
278	Disrupted rich club network in behavioral variant frontotemporal dementia and earlyâ€onset <scp>A</scp>lzheimer's disease. Human Brain Mapping, 2016, 37, 868-883.	1.9	53
279	Potential Pathways of Abnormal Tau and Î±-Synuclein Dissemination in Sporadic Alzheimer's and Parkinson's Diseases. Cold Spring Harbor Perspectives in Biology, 2016, 8, a023630.	2.3	101
280	Copper-induced structural conversion templates prion protein oligomerization and neurotoxicity. Science Advances, 2016, 2, e1600014.	4.7	48
282	Potential of the Antibody Against cisâ€“Phosphorylated Tau in the Early Diagnosis, Treatment, and Prevention of Alzheimer Disease and Brain Injury. JAMA Neurology, 2016, 73, 1356.	4.5	64
283	In vitro prion-like behaviour of TDP-43 in ALS. Neurobiology of Disease, 2016, 96, 236-247.	2.1	118
284	Cell Damage in Light Chain Amyloidosis. Journal of Biological Chemistry, 2016, 291, 19813-19825.	1.6	58

#	Article	IF	Citations
285	HSA targets multiple AÎ²42 species and inhibits the seeding-mediated aggregation and cytotoxicity of AÎ²42 aggregates. RSC Advances, 2016, 6, 71165-71175.	1.7	18
286	Neuroimaging Advances in Alzheimer's Disease. , 2016, , 263-282.		1
287	Progressive Supranuclear Palsy and Related Parkinsonian Disorders. , 2016, , 283-300.		1
288	Protein Folding Activity of the Ribosome is involved in Yeast Prion Propagation. Scientific Reports, 2016, 6, 32117.	1.6	19
289	Alzheimerâ€™s disease AdvaxCpG- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and AÎ² pathological molecules. Scientific Reports, 2016, 6, 28912.	1.6	37
290	Inhibition of Tau Aggregation as a Basis for Treatment and Prevention of Alzheimerâ€™s Disease. , 2016, , 385-436.		1
291	A role for Î²2* nicotinic receptors in a model of local amyloid pathology induced in dentate gyrus. Neurobiology of Aging, 2016, 46, 221-234.	1.5	7
292	The Ubiquitin-Proteasome System and Molecular Chaperone Deregulation in Alzheimerâ€™s Disease. Molecular Neurobiology, 2016, 53, 905-931.	1.9	74
293	Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathologica, 2016, 131, 27-48.	3.9	147
294	A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nature Reviews Neuroscience, 2016, 17, 251-260.	4.9	251
295	Therapeutic approaches in Parkinson's disease andÂrelated disorders. Journal of Neurochemistry, 2016, 139, 346-352.	2.1	46
296	Gene promoter methylation and expression of Pin1 differ between patients with frontotemporal dementia and Alzheimer's disease. Journal of the Neurological Sciences, 2016, 362, 283-286.	0.3	22
297	Combined Isothermal Titration and Differential Scanning Calorimetry Define Three-State Thermodynamics of fALS-Associated Mutant Apo SOD1 Dimers and an Increased Population of Folded Monomer. Biochemistry, 2016, 55, 519-533.	1.2	18
298	Brain metabolism as a modulator of autophagy in neurodegeneration. Brain Research, 2016, 1649, 158-165.	1.1	17
299	Magnetic resonance imaging as a potential biomarker for Parkinson's disease. Translational Research, 2016, 175, 4-16.	2.2	23
300	Based on the Network Degeneration Hypothesis: Separating Individual Patients with Different Neurodegenerative Syndromes in a Preliminary Hybrid PET/MR Study. Journal of Nuclear Medicine, 2016, 57, 410-415.	2.8	50
301	Intrastriatal injection of botulinum neurotoxin-A is not cytotoxic in rat brainÂâ€“ A histological and stereological analysis. Brain Research, 2016, 1630, 18-24.	1.1	19
302	Immunotherapeutic Approaches Targeting Amyloid-Î², Î±-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders. Neurotherapeutics, 2016, 13, 179-189.	2.1	113

#	Article	IF	Citations
303	Yeast buddies helping to unravel the complexity of neurodegenerative disorders. Mechanisms of Ageing and Development, 2017, 161, 288-305.	2.2	34
304	Phosphorylation at Ser8 as an Intrinsic Regulatory Switch to Regulate the Morphologies and Structures of Alzheimer's 40-residue Î²-Amyloid (AÎ²40) Fibrils. Journal of Biological Chemistry, 2017, 292, 2611-2623.	1.6	29
305	Multifactorial causal model of brain (dis)organization and therapeutic intervention: Application to Alzheimerâ€™s disease. NeuroImage, 2017, 152, 60-77.	2.1	107
306	Energy and the Alzheimer brain. Neuroscience and Biobehavioral Reviews, 2017, 75, 297-313.	2.9	32
307	Single cell imaging and quantification of TDP-43 and Î±-synuclein intercellular propagation. Scientific Reports, 2017, 7, 544.	1.6	16
308	Individual Correspondence of Amyloid-Î² and Intrinsic Connectivity in the Posterior Default Mode Network Across Stages of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 58, 763-773.	1.2	30
309	Extracellular Tau Oligomers Induce Invasion of Endogenous Tau into the Somatodendritic Compartment and Axonal Transport Dysfunction. Journal of Alzheimer's Disease, 2017, 58, 803-820.	1.2	51
310	Prion-like mechanisms and potential therapeutic targets in neurodegenerative disorders. , 2017, 172, 22-33.		52
311	Imaging plus X: multimodal models of neurodegenerative disease. Current Opinion in Neurology, 2017, 30, 371-379.	1.8	75
312	Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex. JAMA Neurology, 2017, 74, 813.	4.5	61
313	Yeast genetic interaction screen of human genes associated with amyotrophic lateral sclerosis: identification of MAP2K5 kinase as a potential drug target. Genome Research, 2017, 27, 1487-1500.	2.4	12
314	Toward precision medicine: tailoring interventional strategies based on noninvasive brain stimulation for motor recovery after stroke. Current Opinion in Neurology, 2017, 30, 388-397.	1.8	51
315	Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency. Molecular Neurodegeneration, 2017, 12, 33.	4.4	40
316	The double life of the ribosome: When its protein folding activity supports prion propagation. Prion, 2017, 11, 89-97.	0.9	8
317	Cell-to-cell transfer of SAA1 protein in a cell culture model of systemic AA amyloidosis. Scientific Reports, 2017, 7, 45683.	1.6	8
318	MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice. Vaccine, 2017, 35, 2015-2024.	1.7	20
319	Mapping Neurodegenerative Disease Onset and Progression. Cold Spring Harbor Perspectives in Biology, 2017, 9, a023622.	2.3	67
320	Quantitative neuropathology: an update on automated methodologies and implications for large scale cohorts. Journal of Neural Transmission, 2017, 124, 671-683.	1.4	21

#	Article	IF	Citations
321	Prion-like Protein Seeding and the Pathobiology of Alzheimerâ€™s Disease. , 2017, , 57-82.		0
322	Age-Dependent Alpha-Synuclein Accumulation and Phosphorylation in the Enteric Nervous System in a Transgenic Mouse Model of Parkinsonâ€™s Disease. Neuroscience Bulletin, 2017, 33, 483-492.	1.5	27
323	Applications of Resting-State Functional Connectivity to Neurodegenerative Disease. Neuroimaging Clinics of North America, 2017, 27, 663-683.	0.5	36
324	The vascular facet of late-onset Alzheimer's disease: an essential factor in a complex multifactorial disorder. Current Opinion in Neurology, 2017, 30, 623-629.	1.8	14
325	Cis P-tau is induced in clinical and preclinical brain injury and contributes to post-injury sequelae. Nature Communications, 2017, 8, 1000.	5.8	103
326	Amyloidogenesis of Tau protein. Protein Science, 2017, 26, 2126-2150.	3.1	102
327	Mitochondrial dynamics in Parkinson's disease: a role for Î±-synuclein?. DMM Disease Models and Mechanisms, 2017, 10, 1075-1087.	1.2	134
328	Therapeutic Approaches to Prion Diseases. Progress in Molecular Biology and Translational Science, 2017, 150, 433-453.	0.9	8
329	The Study of Postmortem Human Synaptosomes for Understanding Alzheimerâ€™s Disease and Other Neurological Disorders: A Review. Neurology and Therapy, 2017, 6, 57-68.	1.4	54
330	Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau. Mayo Clinic Proceedings, 2017, 92, 1291-1303.	1.4	50
331	Nuclear but not mitochondrialâ€encoded oxidative phosphorylation genes are altered in aging, mild cognitive impairment, and Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 510-519.	0.4	116
332	White matter structural network abnormalities underlie executive dysfunction in amyotrophic lateral sclerosis. Human Brain Mapping, 2017, 38, 1249-1268.	1.9	22
333	Neurotrophin Signaling and Stem Cellsâ€”Implications for Neurodegenerative Diseases and Stem Cell Therapy. Molecular Neurobiology, 2017, 54, 7401-7459.	1.9	49
334	Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting. Progress in Biophysics and Molecular Biology, 2017, 123, 16-41.	1.4	64
335	Widespread tau seeding activity at early Braak stages. Acta Neuropathologica, 2017, 133, 91-100.	3.9	122
336	Reduced Abundance and Subverted Functions of Proteins in Prion-Like Diseases: Gained Functions Fascinate but Lost Functions Affect Aetiology. International Journal of Molecular Sciences, 2017, 18, 2223.	1.8	9
337	Membrane Trafficking Illuminates a Path to Parkinsonâ€™s Disease. Tohoku Journal of Experimental Medicine, 2017, 242, 63-76.	0.5	36
338	Prelysosomal Compartments in the Unconventional Secretion of Amyloidogenic Seeds. International Journal of Molecular Sciences, 2017, 18, 227.	1.8	24

#	Article	IF	Citations
339	Plasma Exosomes Spread and Cluster Around Î²-Amyloid Plaques in an Animal Model of Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2017, 9, 12.	1.7	57
340	Predictive Model of Spread of Progressive Supranuclear Palsy Using Directional Network Diffusion. Frontiers in Neurology, 2017, 8, 692.	1.1	36
341	Studying tau protein propagation and pathology in the mouse brain using adeno-associated viruses. Methods in Cell Biology, 2017, 141, 307-322.	0.5	23
342	Can brain impermeable BACE1 inhibitors serve as anti-CAA medicine?. BMC Neurology, 2017, 17, 163.	0.8	5
343	Are exosomes the vehicle for protein aggregate propagation in neurodegenerative diseases?. Acta Neuropathologica Communications, 2017, 5, 64.	2.4	56
344	Transmission of Tau Pathology from Human to Rodent Brain: How to Humanise Animal Models for Alzheimerâ€™s Disease Research. , 2017, 07, .		1
346	A method for inferring regional origins of neurodegeneration. Brain, 2018, 141, 863-876.	3.7	37
347	Prionâ€like protein aggregates exploit the RHO GTPase to cofilinâ€1 signaling pathway to enter cells. EMBO Journal, 2018, 37, .	3.5	24
348	Mechanism of aggregation and membrane interactions of mammalian prion protein. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 1927-1935.	1.4	37
349	Delivery systems for theranostics in neurodegenerative diseases. Nano Research, 2018, 11, 5535-5555.	5.8	29
350	Regional expression of genes mediating trans-synaptic alpha-synuclein transfer predicts regional atrophy in Parkinson disease. NeuroImage: Clinical, 2018, 18, 456-466.	1.4	47
351	Prion-like seeding and nucleation of intracellular amyloid-Î². Neurobiology of Disease, 2018, 113, 1-10.	2.1	60
352	Animals and Human Disease: Zoonosis, Vectors, Food-Borne Diseases, and Allergies. , 2018, , 331-354.		0
353	Iron promotes Î±â€synuclein aggregation and transmission by inhibiting <scp>TFEB</scp>â€mediated autophagosomeâ€lysosome fusion. Journal of Neurochemistry, 2018, 145, 34-50.	2.1	40
354	MicroRNA-16 targets mRNA involved in neurite extension and branching in hippocampal neurons during presymptomatic prion disease. Neurobiology of Disease, 2018, 112, 1-13.	2.1	30
355	The release and transmission of amyloid precursor protein via exosomes. Neurochemistry International, 2018, 114, 18-25.	1.9	13
356	The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases. Journal of Neuropathology and Experimental Neurology, 2018, 77, 2-20.	0.9	77
357	Fibre-specific white matter reductions in Alzheimerâ€™s disease and mild cognitive impairment. Brain, 2018, 141, 888-902.	3.7	226

#	Article	IF	Citations
358	Regulation of protein homeostasis by unconventional protein secretion in mammalian cells. Seminars in Cell and Developmental Biology, 2018, 83, 29-35.	2.3	25
359	Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic. Molecular Therapy, 2018, 26, 947-962.	3.7	29
360	Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. Cold Spring Harbor Perspectives in Biology, 2018, 10, a033118.	2.3	616
361	Patterns of symptom development in patients with motor neuron disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 21-28.	1.1	34
362	Oxidative Stress and the Microbiota-Gut-Brain Axis. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-12.	1.9	133
363	Role of viruses, prions and miRNA in neurodegenerative disorders and dementia. VirusDisease, 2018, 29, 419-433.	1.0	9
364	Biomolecular Assemblies: Moving from Observation to Predictive Design. Chemical Reviews, 2018, 118, 11519-11574.	23.0	71
365	Modulating Conformation of AÎ²-Peptide: An Effective Way to Prevent Protein-Misfolding Disease. Inorganic Chemistry, 2018, 57, 13533-13543.	1.9	32
366	Diagnostic challenges in rapidly progressive dementia. Expert Review of Neurotherapeutics, 2018, 18, 761-772.	1.4	29
367	Converging Patterns of Î±-Synuclein Pathology in Multiple System Atrophy. Journal of Neuropathology and Experimental Neurology, 2018, 77, 1005-1016.	0.9	26
369	Evaluation of the Impact of Protein Aggregation on Cellular Oxidative Stress in Yeast. Journal of Visualized Experiments, 2018, , .	0.2	0
370	Models of Network Spread and Network Degeneration in Brain Disorders. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 788-797.	1.1	37
371	The effect of truncation on prion-like properties of Î±-synuclein. Journal of Biological Chemistry, 2018, 293, 13910-13920.	1.6	63
372	Perspectives on How Human Simultaneous Multi-Modal Imaging Adds Directionality to Spread Models of Alzheimerâ€™s Disease. Frontiers in Neurology, 2018, 9, 26.	1.1	4
373	Mathematical Modeling of Protein Misfolding Mechanisms in Neurological Diseases: A Historical Overview. Frontiers in Neurology, 2018, 9, 37.	1.1	43
374	Mechanisms of Î±-Synuclein Induced Synaptopathy in Parkinson's Disease. Frontiers in Neuroscience, 2018, 12, 80.	1.4	255
375	Experimental Intrastriatal Applications of Botulinum Neurotoxin-A: A Review. International Journal of Molecular Sciences, 2018, 19, 1392.	1.8	12
376	Î²-Amyloid Induces Pathology-Related Patterns of Tau Hyperphosphorylation at Synaptic Terminals. Journal of Neuropathology and Experimental Neurology, 2018, 77, 814-826.	0.9	46

#	Article	IF	Citations
377	The role of heparan sulfates in protein aggregation and their potential impact on neurodegeneration. FEBS Letters, 2018, 592, 3806-3818.	1.3	63
378	Familial human prion diseases associated with prion protein mutations Y226X and G131V are transmissible to transgenic mice expressing human prion protein. Acta Neuropathologica Communications, 2018, 6, 13.	2.4	18
379	Quinolinic Acid Amyloid-like Fibrillar Assemblies Seed Î±-Synuclein Aggregation. Journal of Molecular Biology, 2018, 430, 3847-3862.	2.0	43
380	Biology/Disease-Driven Initiative on Protein-Aggregation Diseases of the Human Proteome Project: Goals and Progress to Date. Journal of Proteome Research, 2018, 17, 4072-4084.	1.8	5
381	Altered topology of the functional speech production network in non-fluent/agrammatic variant of PPA. Cortex, 2018, 108, 252-264.	1.1	41
382	Soluble tau aggregates, not large fibrils, are the toxic species that display seeding and crossâ€seeding behavior. Protein Science, 2018, 27, 1901-1909.	3.1	88
383	Computational modelling of pathogenic protein spread in neurodegenerative diseases. PLoS ONE, 2018, 13, e0192518.	1.1	6
384	The cellular and pathologic prion protein. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 153, 21-44.	1.0	19
385	Visualizing modules of coordinated structural brain atrophy during the course of conversion to Alzheimer's disease by applying methodology from gene co-expression analysis. NeuroImage: Clinical, 2019, 24, 101957.	1.4	11
386	Microglia affect Î±-synuclein cell-to-cell transfer in a mouse model of Parkinsonâ€™s disease. Molecular Neurodegeneration, 2019, 14, 34.	4.4	141
387	Efficient RT-QuIC seeding activity for Î±-synuclein in olfactory mucosa samples of patients with Parkinsonâ€™s disease and multiple system atrophy. Translational Neurodegeneration, 2019, 8, 24.	3.6	106
388	The role of mutations associated with familial neurodegenerative disorders on bloodâ€“brain barrier function in an iPSC model. Fluids and Barriers of the CNS, 2019, 16, 20.	2.4	51
389	Connecting environmental exposure and neurodegeneration using cheminformatics and high resolution mass spectrometry: potential and challenges. Environmental Sciences: Processes and Impacts, 2019, 21, 1426-1445.	1.7	13
390	Hypoxia and Inflammation as a Consequence of Î²-Fibril Accumulation: A Perspective View for New Potential Therapeutic Targets. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-10.	1.9	1
391	Diverse Misfolded Conformational Strains and Cross-seeding of Misfolded Proteins Implicated in Neurodegenerative Diseases. Frontiers in Molecular Neuroscience, 2019, 12, 158.	1.4	31
392	Patient-Tailored, Connectivity-Based Forecasts of Spreading Brain Atrophy. Neuron, 2019, 104, 856-868.e5.	3.8	85
393	A MultiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of tau: therapeutic efficacy in PS19 mice. Scientific Reports, 2019, 9, 15455.	1.6	18
394	Therapeutic Vaccines as Novel Immunotherapy. , 2019, , .		1

#	Article	IF	Citations
395	Microbiome Influence in the Pathogenesis of Prion and Alzheimerâ€™s Diseases. International Journal of Molecular Sciences, 2019, 20, 4704.	1.8	42
396	Tauopathies in Traumatic Brain Injury. , 2019, , 113-129.		0
397	Effective connectivity in the default mode network is distinctively disrupted in Alzheimer's diseaseâ€”A simultaneous restingâ€state FDGâ€PET/fMRI study. Human Brain Mapping, 2021, 42, 4134-4143.	1.9	43
398	The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science, 2019, 363, 880-884.	6.0	460
399	Aggregated Tau activates NLRP3â€“ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo. Acta Neuropathologica, 2019, 137, 599-617.	3.9	259
400	A short perspective on the long road to effective treatments for Alzheimer's disease. British Journal of Pharmacology, 2019, 176, 3636-3648.	2.7	17
401	New insights into the role of microRNAs and long noncoding RNAs in most common neurodegenerative diseases. Journal of Cellular Biochemistry, 2019, 120, 8908-8918.	1.2	33
402	A Longitudinal Model for Tau Aggregation in Alzheimerâ€™s Disease Based on Structural Connectivity. Lecture Notes in Computer Science, 2019, 11492, 384-393.	1.0	8
403	Traumatic Brain Injury-related voiding dysfunction in mice is caused by damage to rostral pathways, altering inputs to the reflex pathways. Scientific Reports, 2019, 9, 8646.	1.6	13
404	Subtypes of Alzheimer's Disease Display Distinct Network Abnormalities Extending Beyond Their Pattern of Brain Atrophy. Frontiers in Neurology, 2019, 10, 524.	1.1	52
405	Tau covariance patterns in Alzheimer's disease patients match intrinsic connectivity networks in the healthy brain. NeuroImage: Clinical, 2019, 23, 101848.	1.4	73
406	Neurodegeneration meets immunology â€“ A chemical biology perspective. Bioorganic and Medicinal Chemistry, 2019, 27, 1911-1924.	1.4	0
407	Predictive model of spread of Parkinson's pathology using network diffusion. NeuroImage, 2019, 192, 178-194.	2.1	61
408	Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacy. EBioMedicine, 2019, 42, 157-173.	2.7	38
409	Microglia as modulators of exosomal alpha-synuclein transmission. Cell Death and Disease, 2019, 10, 174.	2.7	142
410	What Happens to Concussed Animals?. , 2019, , 153-204.		0
411	Structural connectivity centrality changes mark the path toward Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 98-107.	1.2	17
412	Solvent Composition Effects on the Structural Properties of the AÎ²42 Monomer from the 3D-RISM-KH Molecular Theory of Solvation. Journal of Physical Chemistry B, 2019, 123, 2491-2506.	1.2	6

#	Article	IF	Citations
413	LOXL1 folding in exfoliation glaucoma. Advances in Protein Chemistry and Structural Biology, 2019, 118, 273-288.	1.0	11
414	Alzheimer's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 231-255.	1.0	415
415	Parkinsonâ€™s disease and multiple system atrophy have distinct Î±-synuclein seed characteristics. Journal of Biological Chemistry, 2019, 294, 1045-1058.	1.6	141
416	Analysis of RNA Expression Profiles Identifies Dysregulated Vesicle Trafficking Pathways in Creutzfeldt-Jakob Disease. Molecular Neurobiology, 2019, 56, 5009-5024.	1.9	16
417	Age-related diseases as vicious cycles. Ageing Research Reviews, 2019, 49, 11-26.	5.0	58
418	TIA1 regulates the generation and response to toxic tau oligomers. Acta Neuropathologica, 2019, 137, 259-277.	3.9	74
419	Editorial: Network Spread Models of Neurodegenerative Diseases. Frontiers in Neurology, 2018, 9, 1159.	1.1	6
420	Fibril formation and therapeutic targeting of amyloid-like structures in a yeast model of adenine accumulation. Nature Communications, 2019, 10, 62.	5.8	48
421	Brain-Gut-Microbiota Axis in Alzheimerâ€™s Disease. Journal of Neurogastroenterology and Motility, 2019, 25, 48-60.	0.8	496
422	Transthyretin Aggregation Pathway toward the Formation of Distinct Cytotoxic Oligomers. Scientific Reports, 2019, 9, 33.	1.6	41
423	Changes in functional and structural brain connectome along the Alzheimerâ€™s disease continuum. Molecular Psychiatry, 2020, 25, 230-239.	4.1	78
424	What is strain in neurodegenerative diseases?. Cellular and Molecular Life Sciences, 2020, 77, 665-676.	2.4	12
425	Traumatic Brain Injury Induces Tau Aggregation and Spreading. Journal of Neurotrauma, 2020, 37, 80-92.	1.7	113
426	In Vitro Conversion Assays Diagnostic for Neurodegenerative Proteinopathies. journal of applied laboratory medicine, The, 2020, 5, 142-157.	0.6	9
427	Cell-free amplification of prions: Where do we stand?. Progress in Molecular Biology and Translational Science, 2020, 175, 325-358.	0.9	7
428	Gray matter atrophy patterns within the cerebellum-neostriatum-cortical network in SCA3. Neurology, 2020, 95, e3036-e3044.	1.5	21
429	Melatonin and Autophagy in Aging-Related Neurodegenerative Diseases. International Journal of Molecular Sciences, 2020, 21, 7174.	1.8	87
430	Plasma Leptin Reflects Progression of Neurofibrillary Pathology in Animal Model of Tauopathy. Cellular and Molecular Neurobiology, 2022, 42, 125-136.	1.7	0

#	Article	IF	Citations
431	LRRK2 and Protein Aggregation in Parkinsonâ€™s Disease: Insights From Animal Models. Frontiers in Neuroscience, 2020, 14, 719.	1.4	13
432	Modulating disease-relevant tau oligomeric strains by small molecules. Journal of Biological Chemistry, 2020, 295, 14807-14825.	1.6	35
433	It's complicated: The relationship between sleep and Alzheimer's disease in humans. Neurobiology of Disease, 2020, 144, 105031.	2.1	61
434	Toward an Early Realâ€Time Quakingâ€Induced Conversionâ€“Based Diagnostic Biomarker for Lewy Bodyâ€“Related Synucleinopathies. Movement Disorders Clinical Practice, 2020, 7, 780-781.	0.8	0
435	Mandelstamâ€“Brillouin Light Scattering in Bovine Serum Albumin Solutions with Different Concentrations in the Vicinity of Thermal Denaturation. Technical Physics, 2020, 65, 1546-1550.	0.2	1
436	Analytical study of Parkinson's diagnosis through classification techniques. AIP Conference Proceedings, 2020, , .	0.3	0
437	Association of APOE e2 genotype with Alzheimerâ€™s and non-Alzheimerâ€™s neurodegenerative pathologies. Nature Communications, 2020, 11, 4727.	5.8	46
438	Trans-synaptic and retrograde axonal spread of Lewy pathology following pre-formed fibril injection in an in vivo A53T alpha-synuclein mouse model of synucleinopathy. Acta Neuropathologica Communications, 2020, 8, 150.	2.4	36
439	From Seeds to Fibrils and Back: Fragmentation as an Overlooked Step in the Propagation of Prions and Prion-Like Proteins. Biomolecules, 2020, 10, 1305.	1.8	12
440	Insoluble Tau From Human FTDP-17 Cases Exhibit Unique Transmission Properties In Vivo. Journal of Neuropathology and Experimental Neurology, 2020, 79, 941-949.	0.9	6
441	Gene Therapy for Neurodegenerative Diseases: Slowing Down the Ticking Clock. Frontiers in Neuroscience, 2020, 14, 580179.	1.4	42
442	A myosin-7Bâ€“dependent endocytosis pathway mediates cellular entry of Î±-synuclein fibrils and polycation-bearing cargos. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 10865-10875.	3.3	37
443	Assessment of Glial Activation Response in the Progress of Natural Scrapie after Chronic Dexamethasone Treatment. International Journal of Molecular Sciences, 2020, 21, 3231.	1.8	9
444	Gut Microbiome-Modified Polyphenolic Compounds Inhibit Î±-Synuclein Seeding and Spreading in Î±-Synucleinopathies. Frontiers in Neuroscience, 2020, 14, 398.	1.4	17
445	Spread of pathological tau proteins through communicating neurons in human Alzheimerâ€™s disease. Nature Communications, 2020, 11, 2612.	5.8	283
446	Selective neuronal vulnerability in Alzheimerâ€™s disease. Ageing Research Reviews, 2020, 62, 101114.	5.0	9
447	Non-motor Clinical and Biomarker Predictors Enable High Cross-Validated Accuracy Detection of Early PD but Lesser Cross-Validated Accuracy Detection of Scans Without Evidence of Dopaminergic Deficit. Frontiers in Neurology, 2020, 11, 364.	1.1	7
448	Bacterial DNA promotes Tau aggregation. Scientific Reports, 2020, 10, 2369.	1.6	43

#	Article	IF	Citations
449	Alzheimerâ€™s disease: review of current nanotechnological therapeutic strategies. Expert Review of Neurotherapeutics, 2020, 20, 271-279.	1.4	22
451	The Evolving Landscape of Exosomes in Neurodegenerative Diseases: Exosomes Characteristics and a Promising Role in Early Diagnosis. International Journal of Molecular Sciences, 2021, 22, 440.	1.8	84
452	Filamentous recombinant human Tau activates primary astrocytes via an integrin receptor complex. Nature Communications, 2021, 12, 95.	5.8	46
453	In vivo Validation of Bimolecular Fluorescence Complementation (BiFC) to Investigate Aggregate Formation in Amyotrophic Lateral Sclerosis (ALS). Molecular Neurobiology, 2021, 58, 2061-2074.	1.9	5
454	Is Exposure to BMAA a Risk Factor for Neurodegenerative Diseases? A Response to a Critical Review of the BMAA Hypothesis. Neurotoxicity Research, 2021, 39, 81-106.	1.3	41
455	Complex Inclusion Bodies and Defective Proteome Hubs in Neurodegenerative Disease: New Clues, New Challenges. Neuroscientist, 2022, 28, 271-282.	2.6	5
456	What is the Pathogenic CAG Expansion Length in Huntingtonâ€™s Disease?. Journal of Huntington's Disease, 2021, 10, 175-202.	0.9	31
458	Brain Molecular Connectivity in Neurodegenerative Conditions. Brain Sciences, 2021, 11, 433.	1.1	7
459	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. Brain Connectivity, 2021, 11, 239-249.	0.8	18
460	Tau induces formation of Î±-synuclein filaments with distinct molecular conformations. Biochemical and Biophysical Research Communications, 2021, 554, 145-150.	1.0	13
461	Graph Models of Pathology Spread in Alzheimer's Disease: An Alternative to Conventional Graph Theoretic Analysis. Brain Connectivity, 2021, 11, 799-814.	0.8	9
462	Overexpression of protein kinase MÎ¶ in the hippocampal dentate gyrus rescues amyloid-Î²-induced synaptic dysfunction within entorhinal-hippocampal circuit. Neurobiology of Aging, 2021, 101, 160-171.	1.5	6
463	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. Brain, 2021, 144, 3212-3225.	3.7	26
464	Emergence of directional bias in tau deposition from axonal transport dynamics. PLoS Computational Biology, 2021, 17, e1009258.	1.5	7
465	Combined Model of Aggregation and Network Diffusion Recapitulates Alzheimer's Regional Tau-Positron Emission Tomography. Brain Connectivity, 2021, 11, 624-638.	0.8	8
466	The human connectome in Alzheimer disease â€” relationship to biomarkers and genetics. Nature Reviews Neurology, 2021, 17, 545-563.	4.9	106
467	Therapeutic Assay with the Non-toxic C-Terminal Fragment of Tetanus Toxin (TTC) in Transgenic Murine Models of Prion Disease. Molecular Neurobiology, 2021, 58, 5312-5326.	1.9	1
468	Network model of pathology spread recapitulates neurodegeneration and selective vulnerability in Huntington's Disease. NeuroImage, 2021, 235, 118008.	2.1	12

#	Article	IF	Citations
469	Waste Clearance in the Brain. Frontiers in Neuroanatomy, 2021, 15, 665803.	0.9	32
470	Time of symptoms beyond the bulbar region predicts survival in bulbar onset amyotrophic lateral sclerosis. Neurological Sciences, 2022, 43, 1817-1822.	0.9	2
471	Longitudinal predictive modeling of tau progression along the structural connectome. NeuroImage, 2021, 237, 118126.	2.1	8
472	Dynamic nanoassembly-based drug delivery systems on the horizon. Journal of Controlled Release, 2021, 339, 547-552.	4.8	5
473	Accumulation of C-terminal cleaved tau is distinctly associated with cognitive deficits, synaptic plasticity impairment, and neurodegeneration in aged mice. GeroScience, 2022, 44, 173-194.	2.1	6
474	Dynamic nanoassemblies for imaging and therapy of neurological disorders. Advanced Drug Delivery Reviews, 2021, 175, 113832.	6.6	15
475	A multiparametric MRI study of structural brain damage in dementia with lewy bodies: A comparison with Alzheimer's disease. Parkinsonism and Related Disorders, 2021, 91, 154-161.	1.1	3
476	Astrocytes in Neurodegenerative Diseases: A Perspective from Tauopathy and Î±-Synucleinopathy. Life, 2021, 11, 938.	1.1	13
477	Impact of Sterilization Methods on the Seeding Ability of Human Tau Proteopathic Seeds. Journal of Neuropathology and Experimental Neurology, 2021, 80, 912-921.	0.9	0
478	All Roads Lead to Rome: Different Molecular Players Converge to Common Toxic Pathways in Neurodegeneration. Cells, 2021, 10, 2438.	1.8	22
479	Network-constrained technique to characterize pathology progression rate in Alzheimerâ€™s disease. Brain Communications, 2021, 3, fcab144.	1.5	3
480	Human Sporadic Prion Diseases. , 2013, , 59-72.		4
481	Glymphatic System. , 2015, , 1-18.		2
482	A Physics-Informed Geometric Learning Model for Pathological Tau Spread in Alzheimerâ€™s Disease. Lecture Notes in Computer Science, 2020, 12267, 418-427.	1.0	2
483	The Pattern of Cortical Lesions in Preclinical Stages. Advances in Anatomy, Embryology and Cell Biology, 2015, , 57-73.	1.0	1
484	Aetiopathogenesis. , 2014, , 57-81.		3
485	Overview of Fibrillar and Oligomeric Assemblies of Amyloidogenic Proteins. , 2012, , 1-36.		3
486	Role of Prion Protein Oligomers in the Pathogenesis of Transmissible Spongiform Encephalopathies. , 2012, , 319-335.		6

#	Article	IF	Citations
487	Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease. Advances in Experimental Medicine and Biology, 2019, 1184, 145-166.	0.8	11
488	Tau Prion-Like Propagation: State of theÂArt and Current Challenges. Advances in Experimental Medicine and Biology, 2019, 1184, 305-325.	0.8	47
489	Heterogeneous Nuclear Ribonucleoproteins: Implications in Neurological Diseases. Molecular Neurobiology, 2021, 58, 631-646.	1.9	37
490	Protein Misfolding Cyclic Amplification of Infectious Prions. Progress in Molecular Biology and Translational Science, 2017, 150, 361-374.	0.9	6
491	Astroglial contribution to tau-dependent neurodegeneration. Biochemical Journal, 2019, 476, 3493-3504.	1.7	17
492	Evidence for sortilin modulating regional accumulation of human tau prions in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E11029-E11036.	3.3	23
493	The mechanisms of prion disease.. CAB Reviews: Perspectives in Agriculture, Veterinary Science, Nutrition and Natural Resources, 0, , 1-34.	0.6	4
494	Structural and dynamical mechanisms of a naturally occurring variant of the human prion protein in preventing prion conversion. Chinese Physics B, 2020, 29, 108710.	0.7	5
500	Misfolded Proteins in Neurodegenerative Dementias: Molecular Mechanisms. Dementia and Neurocognitive Disorders, 2012, 11, 38.	0.4	2
501	Superoxide Dismutase 1 and tgSOD1G93A Mouse Spinal Cord Seed Fibrils, Suggesting a Propagative Cell Death Mechanism in Amyotrophic Lateral Sclerosis. PLoS ONE, 2010, 5, e10627.	1.1	113
502	Gene Expression Profiling and Association with Prion-Related Lesions in the Medulla Oblongata of Symptomatic Natural Scrapie Animals. PLoS ONE, 2011, 6, e19909.	1.1	19
503	The AAA-ATPase VPS4 Regulates Extracellular Secretion and Lysosomal Targeting of Î±-Synuclein. PLoS ONE, 2011, 6, e29460.	1.1	120
504	Snord 3A: A Molecular Marker and Modulator of Prion Disease Progression. PLoS ONE, 2013, 8, e54433.	1.1	14
505	Glycoform-Selective Prion Formation in Sporadic and Familial Forms of Prion Disease. PLoS ONE, 2013, 8, e58786.	1.1	32
506	The Toll-Like Receptor Agonist Imiquimod Is Active against Prions. PLoS ONE, 2013, 8, e72112.	1.1	26
507	pH-Driven Polymorphism of Insulin Amyloid-Like Fibrils. PLoS ONE, 2015, 10, e0136602.	1.1	53
508	Functional Amyloids and their Possible Influence on Alzheimer Disease. Discoveries, 2017, 5, e79.	1.5	9
509	New Insight in The Molecular Mechanisms of Neurodegenerative Disease. Indonesian Biomedical Journal, 2018, 10, 16.	0.2	3

#	Article	IF	Citations
510	Altered filamin A enables amyloid beta-induced tau hyperphosphorylation and neuroinflammation in Alzheimerâ€™s disease. Neuroimmunology and Neuroinflammation, 2017, 4, 263.	1.4	17
511	A New Interpretative Paradigm for Conformational Protein Diseases. Current Protein and Peptide Science, 2013, 14, 141-160.	0.7	5
512	Ubiquitination and SUMOylation of Amyloid and Amyloid-like Proteins in Health and Disease. Current Issues in Molecular Biology, 2020, 35, 195-230.	1.0	5
513	Molecular Basis of Amyloid Polymorphism: Multiple Misfolding Pathways. , 2013, 03, .		1
514	Differences in topological progression profile among neurodegenerative diseases from imaging data. ELife, 2019, 8, .	2.8	11
515	Viral alpha-synuclein knockdown prevents spreading synucleinopathy. Brain Communications, 2021, 3, fcab247.	1.5	5
516	Transposable elements as new players in neurodegenerative diseases. FEBS Letters, 2021, 595, 2733-2755.	1.3	24
518	Infectious and Pathogenic Forms of PrP. , 2013, , 135-146.		0
519	Amyloid-Î² Transmissibility. Research and Perspectives in Alzheimer's Disease, 2013, , 71-86.	0.1	0
520	Conformational Disease and RNA Disease Theory in the Context of Neurodegenerative Diseases. , 2015, , 3-22.		0
522	Propagated protein misfolding: New opportunities for therapeutics, new public health risk. Canada Communicable Disease Report, 2015, 41, 196-199.	0.6	5
523	Glymphatic System. , 2016, , 1945-1962.		0
524	Computational Modelling of Pathogenic Protein Behaviour-Governing Mechanisms in the Brain. Lecture Notes in Computer Science, 2018, , 532-539.	1.0	0
525	Therapeutic Vaccines Targeting Alzheimerâ€™s Disease. , 2019, , 9-20.		1
526	Patient-Tailored, Connectivity-Based Forecasts of Spreading Brain Atrophy. SSRN Electronic Journal, 0, , .	0.4	1
527	Brain Network Functional Connectivity in Alzheimerâ€™s Disease and Frontotemporal Dementia. , 2020, , 385-415.		1
530	CHAPTER 7. Neuroinflammation and Oxidative Stress in Models of Parkinsonâ€™s Disease and Protein-Misfolding Disorders. Issues in Toxicology, 0, , 184-209.	0.2	1
531	Launch of american journal of neurodegenerative disease. American Journal of Neurodegenerative Disease, 2012, 1, i-ii.	0.1	0

#	Article	IF	Citations
532	Calcium Channel Blockade Ameliorates Endoplasmic Reticulum Stress in the Hippocampus Induced by Amyloidopathy in the Entorhinal Cortex. Iranian Journal of Pharmaceutical Research, 2019, 18, 1466-1476.	0.3	2
533	Visualizing Neurodegenaration Using Atomic Force Microscopy. , 2021, , 1-21.		0
534	A {Cd₄Cl₂O₁₄} cluster functionalized sandwich-type tungstoarsenate as a conformation modulator for misfolding AÎ² peptides. CrystEngComm, 2022, 24, 1171-1176.	1.3	7
535	Photo-Oxygenation: An Innovative New Therapeutic Approach Against Amyloidoses. Advances in Experimental Medicine and Biology, 2021, 1339, 415-422.	0.8	2
536	Sublethal enteroviral infection exacerbates disease progression in an ALS mouse model. Journal of Neuroinflammation, 2022, 19, 16.	3.1	7
538	Age-dependent aggregation of Î±-synuclein in the nervous system of gut-brain axis is associated with caspase-1 activation. Metabolic Brain Disease, 2022, 37, 1669-1681.	1.4	2
539	The role of disrupted functional connectivity in aphasia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2022, 185, 99-119.	1.0	2
540	Signature laminar distributions of pathology in frontotemporal lobar degeneration. Acta Neuropathologica, 2022, 143, 363-382.	3.9	12
541	The AÎ²1â€“42/AÎ²1â€“40 ratio in CSF is more strongly associated to tau markers and clinical progression than AÎ²1â€“42 alone. Alzheimer's Research and Therapy, 2022, 14, 20.	3.0	18
542	The Potential Role of Gut Microbiota in Alzheimerâ€™s Disease: From Diagnosis to Treatment. Nutrients, 2022, 14, 668.	1.7	79
543	A nanoscale polymolybdate builded by two hexavacant Keggin-type fragments via a novel {Ca6P6O38} cluster with Î²-sheet conformation modulation ability. CrystEngComm, 0, , .	1.3	4
544	Small but Mightyâ€”Exosomes, Novel Intercellular Messengers in Neurodegeneration. Biology, 2022, 11, 413.	1.3	15
545	Caffeine Consumption and Dementia: Are Lewy Bodies the Link?. Annals of Neurology, 2022, 91, 834-846.	2.8	4
546	Propagation of tau and Î±-synuclein in the brain: therapeutic potential of the glymphatic system. Translational Neurodegeneration, 2022, 11, 19.	3.6	15
547	Remarkable difference of phospholipid molecular chirality in regulating PrP aggregation and cell responses. Chinese Chemical Letters, 2023, 34, 107332.	4.8	3
548	Proteomic analysis of heat-stable proteins revealed an increased proportion of proteins with compositionally biased regions. Scientific Reports, 2022, 12, 4347.	1.6	2
549	Molecular crowding and RNA synergize to promote phase separation, microtubule interaction, and seeding of Tau condensates. EMBO Journal, 2022, 41, e108882.	3.5	33
550	A transdiagnostic review of neuroimaging studies of apathy and disinhibition in dementia. Brain, 2022, 145, 1886-1905.	3.7	15

#	Article	IF	Citations
551	Modelling female physiology from head to Toe: Impact of sex hormones, menstrual cycle, and pregnancy. Journal of Theoretical Biology, 2022, 540, 111074.	0.8	13
553	AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System. Frontiers in Neurology, 2022, 13, 870799.	1.1	4
554	Exploiting Focused Ultrasound to Aid Intranasal Drug Delivery for Brain Therapy. Frontiers in Pharmacology, 2022, 13, 786475.	1.6	3
563	Clinical and Preclinical Studies of Fermented Foods and Their Effects on Alzheimerâ€™s Disease. Antioxidants, 2022, 11, 883.	2.2	21
564	Significance of Brain Glucose Hypometabolism, Altered Insulin Signal Transduction, and Insulin Resistance in Several Neurological Diseases. Frontiers in Endocrinology, 2022, 13, .	1.5	20
565	Default Mode Network quantitative diffusion and restingâ€state functional magnetic resonance imaging correlates in sporadic Creutzfeldtâ€Jakob disease. Human Brain Mapping, 0, , .	1.9	4
566	Silver nanoparticle-deposited whey protein isolate amyloid fibrils as catalysts for the reduction of methylene blue. International Journal of Biological Macromolecules, 2022, 213, 1098-1114.	3.6	11
567	EEG Resting-State Functional Networks in Amnestic Mild Cognitive Impairment. Clinical EEG and Neuroscience, 2023, 54, 36-50.	0.9	7
570	Security breach: peripheral nerves provide unrestricted access for toxin delivery into the central nervous system. Neural Regeneration Research, 2023, 18, 64.	1.6	0
571	Enriched environment ameliorates propagation of tau pathology and improves cognition in rat model of tauopathy. Frontiers in Aging Neuroscience, 0, 14, .	1.7	1
573	Disease-associated mutations within the yeast DNAJB6 homolog Sis1 slow conformer-specific substrate processing and can be corrected by the modulation of nucleotide exchange factors. Nature Communications, 2022, 13, .	5.8	2
574	Catechol-containing compounds are a broad class of protein aggregation inhibitors: Redox state is a key determinant of the inhibitory activities. Pharmacological Research, 2022, 184, 106409.	3.1	6
575	Motor cortical patterns of upper motor neuron pathology in amyotrophic lateral sclerosis: A 3ÂT MRI study with iron-sensitive sequences. NeuroImage: Clinical, 2022, 35, 103138.	1.4	5
576	The Role of Glymphatic System in Alzheimerâ€™s and Parkinsonâ€™s Disease Pathogenesis. Biomedicines, 2022, 10, 2261.	1.4	19
577	Passive Immunotherapy Targeting Tau Oligomeric Strains Reverses Tauopathy Phenotypes in Aged Human-Tau Mice in a Mouse Model-Specific Manner. Journal of Alzheimer's Disease, 2022, 90, 1103-1122.	1.2	11
578	TauLUM, an inÂvivo Drosophila sensor of tau multimerization, identifies neuroprotective interventions in tauopathy. Cell Reports Methods, 2022, 2, 100292.	1.4	3
579	Loss of forebrain BIN1 attenuates hippocampal pathology and neuroinflammation in a tauopathy model. Brain, 2023, 146, 1561-1579.	3.7	12
580	Glymphatic System. , 2022, , 2271-2288.		0

#	Article	IF	Citations
581	Immunogenicity of MultiTEP platform technology-based Tau vaccine in non-human primates. Npj Vaccines, 2022, 7, .	2.9	5
582	Intestine-derived Î±-synuclein initiates and aggravates pathogenesis of Parkinsonâ€™s disease in Drosophila. Translational Neurodegeneration, 2022, 11, .	3.6	13
583	Using FRET-Based Biosensor Cells to Study the Seeding Activity of Tau and Î±-Synuclein. Methods in Molecular Biology, 2023, , 125-145.	0.4	5
584	Linking Puberty and the Gut Microbiome to the Pathogenesis of Neurodegenerative Disorders. Microorganisms, 2022, 10, 2163.	1.6	4
585	Liquidâ€“liquid phase separation in neurodegenerative diseases. , 2023, , 619-650.		1
586	Case Report: Three Case Reports of Rapidly Progressive Dementias and Narrative Review. Case Reports in Neurology, 2022, 14, 441-455.	0.3	1
587	Essential Components of Synthetic Infectious Prion Formation De Novo. Biomolecules, 2022, 12, 1694.	1.8	1
588	New Insights into the Gut Microbiota in Neurodegenerative Diseases from the Perspective of Redox Homeostasis. Antioxidants, 2022, 11, 2287.	2.2	8
589	Metformin Attenuates Tau Pathology in Tau-Seeded PS19 Mice. Neurotherapeutics, 2023, 20, 452-463.	2.1	2
590	Sex-Specific Multiparameter Blood Test for the Early Diagnosis of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 15670.	1.8	6
591	The effects of microglia on tauopathy progression can be quantified using Nexopathy in silico (Nexis) models. Scientific Reports, 2022, 12, .	1.6	5
592	Neuroinflammation is independently associated with brain network dysfunction in Alzheimerâ€™s disease. Molecular Psychiatry, 2023, 28, 1303-1311.	4.1	22
593	Prion Conversion and Deformed Templating. , 2023, , 89-105.		0
594	Animal Models and the Pathogenesis of Parkinson's Disease. , 2011, , 113-161.		0
595	The pollutome-connectome axis: a putative mechanism to explain pollution effects on neurodegeneration. Ageing Research Reviews, 2023, 86, 101867.	5.0	4
596	Structural Proteomic Profiling of Cerebrospinal Fluids to Reveal Novel Conformational Biomarkers for Alzheimerâ€™s Disease. Journal of the American Society for Mass Spectrometry, 2023, 34, 459-471.	1.2	0
597	Employing nanoparticle tracking analysis of salivary neuronal exosomes for early detection of neurodegenerative diseases. Translational Neurodegeneration, 2023, 12, .	3.6	8
598	Network of hotspot interactions cluster tau amyloid folds. Nature Communications, 2023, 14, .	5.8	10

#	Article	IF	Citations
599	A Nanoenzyme Constructed from Manganese and Strandberg-Type Phosphomolybdate with Versatility in Antioxidant and Modulating Conformation of AÎ² Protein Misfolding Aggregates In Vitro. International Journal of Molecular Sciences, 2023, 24, 4317.	1.8	2
600	Comprehensive Perspective Towards the Management of Proteinopathies by Elucidating Protein Misfolding and Aggregation. CNS and Neurological Disorders - Drug Targets, 2024, 23, 153-180.	0.8	1
601	TGF-Î²1 signalling in Alzheimerâ€™s pathology and cytoskeletal reorganization: a specialized Tau perspective. Journal of Neuroinflammation, 2023, 20, .	3.1	16
602	Biomarcadores diagnÃ³sticos de la enfermedad de Creutzfeld-Jakob. Revista De Medicina De Laboratorio, 2023, , .	0.0	0
607	Fluid and Biopsy Based Biomarkers in Parkinson's Disease. Neurotherapeutics, 2023, 20, 932-954.	2.1	6
612	Visualizing Neurodegeneration Using Atomic Force Microscopy. , 2023, , 481-501.		0
620	Molecular pathology of neurodegenerative diseases by cryo-EM of amyloids. Nature, 2023, 621, 701-710.	13.7	18
622	Exosomal MicroRNAs as Brain Memory Devices. , 2023, , 83-105.		0
637	Data-driven modelling of neurodegenerative disease progression: thinking outside the black box. Nature Reviews Neuroscience, 2024, 25, 111-130.	4.9	0